Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T LiEgbert F SmitYasushi GotoKazuhiko NakagawaHibiki UdagawaJulien MazièresMisako NagasakaLyudmila BazhenovaAndreas N SaltosEnriqueta FelipJose M PachecoMaurice PérolLuis Paz-AresKapil SaxenaRyota ShigaYingkai ChengSuddhasatta AcharyyaPatrik VitazkaJavad ShahidiDavid PlanchardPasi A Jännenull nullPublished in: The New England journal of medicine (2021)
Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Lung01 ClinicalTrials.gov number, NCT03505710.).